An Observational Study of Patients With Chronic Liver Disease
1 other identifier
observational
500,000
1 country
10
Brief Summary
TARGET-Liver Disease (TARGET-LD) is an observational research study to conduct a comprehensive review of outcomes for patients with chronic liver disease (CLD).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2024
Longer than P75 for all trials
10 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 15, 2023
CompletedFirst Posted
Study publicly available on registry
February 27, 2023
CompletedStudy Start
First participant enrolled
February 19, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2037
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2037
March 3, 2026
March 1, 2026
13.9 years
February 15, 2023
March 2, 2026
Conditions
Outcome Measures
Primary Outcomes (3)
To characterize the natural history of disease in patients with CLD from various etiologies and Cirrhosis
20 Years
To assess safety and effectiveness of CLD/Cirrhosis treatments and treatments for complications of any chronic liver disease
20 Years
To establish learning health networks focused on quality of care for patients
20 Years
Secondary Outcomes (2)
To evaluate provider management practices in the treatment of patients with CLD/Cirrhosis
20 Years
To evaluate longitudinal and patient reported outcomes in CLD/Cirrhosis
20 Years
Study Arms (2)
Disease Cohort
Engaged Cohort
Interventions
Eligibility Criteria
The study will include adults who are being managed for chronic liver disease or cirrhosis of any etiology.
You may qualify if:
- Disease Cohort
- Adult\* patients at the time of enrollment with a diagnosis of CLD/cirrhosis by ICD-10 code in the EHR interface
- Engaged Cohort
- Adult\* patients diagnosed and managed for CLD/cirrhosis invited to participate
- Ability to provide written informed consent
You may not qualify if:
- Disease Cohort
- Death
- Manual removal (sponsor or site request)
- No EHR interface encounter \> 3 years.
- Engaged Cohort
- Patient expressed desire to withdraw consent to complete PROs
- Failure to complete PROs within 24 weeks of initial invitation
- Greater than 24 months lapse of survey completion after baseline surveys completed
- Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (10)
Keck School of Medicine of USC
Los Angeles, California, 90033, United States
Stanford Medicine
Redwood City, California, 94063, United States
Georgetown Medstar Transplant Institute
Washington D.C., District of Columbia, 20007, United States
Rush University Medical Center
Chicago, Illinois, 60612, United States
Columbia University Irving Medical Center/ New York Presbyterian Hospital
New York, New York, 10032, United States
Atrium Health Center for Liver Disease and Transplant
Charlotte, North Carolina, 28204, United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Temple University - Lewis Katz School of Medicine
Philadelphia, Pennsylvania, 19140, United States
Baylor Scott & White Research Institute
Dallas, Texas, 75246, United States
Baylor College of Medicine
Houston, Texas, 77021, United States
Biospecimen
Whole blood Serum
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 15, 2023
First Posted
February 27, 2023
Study Start
February 19, 2024
Primary Completion (Estimated)
December 31, 2037
Study Completion (Estimated)
December 31, 2037
Last Updated
March 3, 2026
Record last verified: 2026-03